MBBS, MRCP (UK), M Med (Internal Medicine), FAMS
Specialty: Medical Oncology
Sub-specialties: Breast, Gynae-Oncology
Conditions Treated by this Doctor:
Breast Cancer, Cervical Cancer, Ovarian Cancer, Uterine Cancer.
Dr Jack Chan is a Consultant Medical Oncologist who practises at NCCS and KKWCH. He completed his specialist training at NCCS, and is a Fellow of the Academy of Medicine, Singapore. He did a fellowship in early drug development and translational medicine in gynaecological cancers at Cancer Research UK Edinburgh Centre and Edinburgh Cancer Centre under the Health Manpower Development Plan Award.
Dr Chan's subspecialty interests are gynaecological cancers and breast cancer. His research interests include early and late phase clinical trials and translational work in these cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at NCCS. Dr Chan is also active in teaching Senior Residents, medical officers, medical and nursing students; as well as in professional societies such as Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He has received accolades for his education and clinical work, including Residency in SingHealth Excels Outstanding Faculty Award 2020 and Singapore Health Quality Service Awards (Silver 2019, Gold 2020, Star 2022).
Dr Chan believes in taking a personalised approach to cancer care. He strives to support patients and their families through navigating the cancer journey by addressing patients' medical needs and quality of life.
· Member, Young College of Physicians Committee, College of Physicians, Academy of Medicine Singapore· Member, Pharmacy Cost Review Workgroup, NCCS· Executive Committee Member, Singapore General Hospital (SGH) Campus, Institution Junior Doctors Well-being Committee· Co-Chairperson, Resource Optimisation Workgroup, NCCS· Member, Cancer Education and Information Service Advisory Committee, NCCS· Co-Chairperson, Breast Cancer Awareness Month Committee, NCCSClinical Core Faculty Member, SingHealth Medical Oncology Residency Programme
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02) (ClinicalTrials.gov Identifier: NCT04620954) (Principal Investigator
Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01) (ClinicalTrials.gov Identifier: NCT03100006) (Principal Investigator)
Subscribe to our mailing list to get the updates to your email inbox...
30 Hospital Boulevard, 168583 +65 6436 8000